ClinicalTrials.gg
RecruitingNCT06548256Updated Aug 12, 2024

The Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease

An interventional study of Miyarisan-BM (Clostridium Butyricum Miyairi) in Clostridium Butyricum Miyairi and Parkinson Disease, sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2023, registered May 2024).
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
20 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies in Parkinson Disease with a site in Taiwan — 33 open to participants now, 37 under way, 1 of them phase 3. Parkinson Disease · Taiwan.

Planned enrollment
5th of 99
400 · median 55
Started
2023
with 8 others
No phase
72 of 121
23 open now
Primary completion
2026-12
later than 17 of 36 live
Registered
97th of 121
by date

Among the 121 studies in Parkinson Disease with a site in Taiwan, this one is the 5th largest by planned enrollment of the 99 interventional ones that give a count, is one of 9 that started in 2023, is one of 72 with no phase, reaches primary completion later than 17 of the 36 other live ones, and was the 97th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

33 of the 121 studies in Parkinson Disease with a site in Taiwan are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 20 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Parkinson Disease with a site in Taiwan, or all of them as a file.
02

Study summary

This is an open-label, single-center, non-randomized study to assess the efficacy of Clostridium Butyricum Miyairi on the motor and non-motor symptoms of Parkinson's disease

Read the detailed description

The physician will explain the trial procedures in the outpatient, and then obtain the written informed consent to start the interview. And randomly divided into experimental and observation groups, and according to the timing of taking Miyarisan, scale evaluation and sample collection.

03

Conditions studied

  • Clostridium Butyricum Miyairi
  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female over 20 years old, diagnosed with Parkinson's disease.

Exclusion criteria

Exclusion Criteria:

  • People with Parkinson's disease Dementia, or Lactose Intolerance
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Miyarisan-BM (Clostridium Butyricum Miyairi) first

    Miyarisan-BM (Clostridium Butyricum Miyairi) for 1 year, then stopped for 1 year

    Drug: Miyarisan-BM (Clostridium Butyricum Miyairi)

  • Experimental
    Miyarisan-BM (Clostridium Butyricum Miyairi) later

    observation for 1 year and then Miyarisan-BM (Clostridium Butyricum Miyairi) for 1 year.

    Drug: Miyarisan-BM (Clostridium Butyricum Miyairi)

Interventions

  • DrugMiyarisan-BM (Clostridium Butyricum Miyairi)

    probiotics

06

What researchers measure

Primary outcomes

  1. MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3

    Part 3 of this scale assesses motor performance in 33 items. Each item is scored on a scale of 0 (normal) to 4 (severe), with a total score range of 0 to 132, and higher scores mean the patient's situation is worse.

    Time frame: 0, 3, 12, 15, 24 months

  2. Hamilton Depression Rating Scale (HAM-D)

    This scale assesses non-motor symptoms in 17 items, the total scale value is 50 (Scores 0 to 7 mean normal, 8 to 13 mean mild depression, 14 to 18 mean moderate depression, 19 to 22 mean severe depression, and ≥23 mean very severe depression).

    Time frame: 0, 3, 12, 15, 24 months

  3. Hamilton Anxiety Scale (HAM-A)

    This scale assesses non-motor symptoms in 14 items. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where ≤17 indicates mild anxiety severity, 18-24 indicate mild to moderate anxiety severity, 25-30 indicate moderate to severe anxiety severity, \>30 indicate severe anxiety.

    Time frame: 0, 3, 12, 15, 24 months

07

Study locations

1 of 1 sites recruiting
  • Kaohsiung Medical Univeristy Hospital
    Kaohsiung city, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 38 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
Aug 12, 2024
StartActual
Oct 31, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06548256
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Oct 31, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 12, 2024

Study contacts

Yang-Pei Chang, M.D.; MSc.
Contact
cyp905@gmail.com
886-7-2911101 ext. 8913

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion